The osteoporosis drug, Zometa, reduces risk of breast cancer recurrence in patients receiving either Arimidex or Tamoxifen, according to a study published in the June 4th The Lancet Oncology. Aromatase inhibitors such as Arimidex which are given to post-menopausal, hormone receptor positive women, are associated with an increased risk of osteoporosis. Bisphosphonates such as Zometa are often given to reduce this risk. They aren’t usually given to women receiving Tamoxifen as it isn’t associated with osteoporosis. However, according to the study, one additional benefit is a significant increase in disease-free survival even two years after Zometa treatment was discontinued.
Link to Medline Health News Report